# JANX (Janux Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Janux Therapeutics, Inc. reported $23.29M in revenue and a net loss of $99.85M for the trailing twelve months ended September 30, 2026 (down 7.1% year over year), with a -599.3% operating margin.

- Canonical: https://convexityos.com/fundamentals/JANX
- Markdown: https://convexityos.com/fundamentals/JANX.md
- SEC CIK: 0001817713
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:33 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001817713&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $23.29M | -7.1% YoY |
| Operating Income | TTM | -$139.6M | -599.3% margin |
| Net Income | TTM | -$99.85M | -428.7% net margin |
| Diluted EPS | TTM | -$1.58 | Split-adjusted |
| Free Cash Flow | TTM | -$54.16M | -232.6% FCF margin |
| Cash & ST Investments | Sep 30, 2026 | $945.7M | Total debt: $20.38M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $10.00M | $10.59M | $8.08M | $8.61M | $3.64M | $0 |
| Research & Development | $125.9M | $68.39M | $54.92M | $53.44M | $26.24M | $3.04M |
| **Operating Income** | -$157.7M | -$98.85M | -$72.98M | -$67.09M | -$32.93M | -$4.84M |
| **EBITDA** | -$155.6M | -$96.79M | -$71.02M | -$66.25M | -$32.82M | -$4.83M |
| Income Tax Expense | $0 | $0 | $0 | -- | -- | -- |
| **Net Income** | -$113.6M | -$68.99M | -$58.29M | -$63.06M | -$32.67M | -$6.78M |
| Basic EPS | -$1.83 | -$1.28 | -$1.32 | -$1.52 | -$1.39 | -$5.78 |
| **Diluted EPS** | -$1.83 | -$1.28 | -$1.32 | -$1.52 | -$1.39 | -$5.78 |
| Basic Shares Outstanding | 62.0M | 53.8M | 44.0M | 41.5M | 23.5M | 299.4K |
| Diluted Shares Outstanding | 62.0M | 53.8M | 44.0M | 41.5M | 23.5M | 1.2M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $9.29M | $10.27M | $3.73M | $0 | $10.00M | $0 | $0 | $0 |
| Research & Development | $30.57M | $30.99M | $26.81M | $31.55M | $34.63M | $34.66M | $25.05M | $20.81M |
| **Operating Income** | -$31.26M | -$31.69M | -$34.21M | -$42.40M | -$35.25M | -$45.12M | -$34.90M | -$29.02M |
| **EBITDA** | -$30.80M | -$31.23M | -$33.74M | -$41.93M | -$34.75M | -$44.58M | -$34.38M | -$28.51M |
| **Net Income** | -$21.57M | -$21.97M | -$24.36M | -$31.95M | -$24.31M | -$33.86M | -$23.51M | -$20.22M |
| Basic EPS | -$0.34 | -$0.35 | -$0.39 | -- | -$0.39 | -$0.55 | -$0.38 | -- |
| **Diluted EPS** | -$0.34 | -$0.35 | -$0.39 | -- | -$0.39 | -$0.55 | -$0.38 | -- |
| Basic Shares Outstanding | 63.1M | 62.9M | 62.7M | -- | 62.0M | 61.9M | 61.8M | -- |
| Diluted Shares Outstanding | 63.1M | 62.9M | 62.7M | -- | 62.0M | 61.9M | 61.8M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $52.33M | $430.6M | $19.20M | $51.43M | $35.58M | $7.81M |
| Short-Term Investments | $914.2M | $594.6M | $324.8M | $275.6M | $339.4M | $0 |
| **Cash & Short-Term Investments** | $966.6M | $1.03B | $344.0M | $327.0M | $375.0M | $7.81M |
| Accounts Receivable, Net | $0 | -- | $0 | $0 | $0 | $8.00M |
| **Total Current Assets** | $975.9M | $1.03B | $349.2M | $332.4M | $377.0M | $16.06M |
| Property, Plant & Equipment, Net | $3.85M | $4.86M | $7.00M | $7.09M | $1.41M | $155K |
| Other Non-Current Assets | $2.61M | $2.88M | $2.51M | $1.39M | $392K | $0 |
| **Total Non-Current Assets** | $25.68M | $27.85M | $31.17M | $31.57M | $2.81M | $155K |
| **Total Assets** | $1.00B | $1.06B | $380.4M | $364.0M | $379.8M | $16.22M |
| Accounts Payable | $4.97M | $4.03M | $2.42M | $2.16M | $2.46M | $428K |
| Deferred Revenue (Current) | $0 | $0 | $1.71M | $5.41M | $5.16M | $1.95M |
| **Total Current Liabilities** | $25.00M | $17.46M | $13.03M | $16.51M | $12.80M | $3.18M |
| Deferred Revenue (Non-Current) | $0 | -- | $0 | $2.22M | $700K | $6.05M |
| **Total Non-Current Liabilities** | $19.75M | $21.28M | $23.02M | $26.76M | $700K | $6.05M |
| **Total Liabilities** | $44.74M | $38.73M | $36.06M | $43.27M | $13.50M | $9.23M |
| **Total Debt (incl. Leases)** | $22.14M | $23.02M | $24.54M | $25.30M | $194K | -- |
| Common Stock | $60K | $59K | $46K | $42K | $41K | $1.0K |
| Retained Earnings | -$351.4M | -$237.8M | -$168.8M | -$110.5M | -$47.41M | -$14.74M |
| Accumulated Other Comp. Income | $4.32M | $2.16M | $665K | -$1.53M | -$270K | $0 |
| **Total Stockholders' Equity** | $956.8M | $1.02B | $344.3M | $320.7M | $366.3M | -$14.64M |
| Total Equity | $956.8M | $1.02B | $344.3M | $320.7M | $366.3M | -$14.64M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $41.82M | $27.77M | $51.83M | $52.33M | $48.39M | $52.45M | $73.74M | $430.6M |
| Short-Term Investments | $903.9M | $943.1M | $904.6M | $914.2M | $940.6M | $943.6M | $940.4M | $594.6M |
| **Cash & Short-Term Investments** | $945.7M | $970.9M | $956.4M | $966.6M | $989.0M | $996.0M | $1.01B | $1.03B |
| Accounts Receivable, Net | $411K | $149K | $35.00M | $0 | -- | -- | -- | -- |
| **Total Current Assets** | $959.4M | $983.3M | $1.00B | $975.9M | $998.1M | $1.01B | $1.02B | $1.03B |
| Property, Plant & Equipment, Net | $2.79M | $3.26M | $3.55M | $3.85M | $4.31M | $4.69M | $4.95M | $4.86M |
| Other Non-Current Assets | $3.89M | $2.91M | $3.94M | $2.61M | $2.63M | $2.69M | $2.79M | $2.88M |
| **Total Non-Current Assets** | $24.27M | $24.32M | $26.18M | $25.68M | $26.68M | $26.66M | $27.43M | $27.85M |
| **Total Assets** | $983.7M | $1.01B | $1.03B | $1.00B | $1.02B | $1.03B | $1.05B | $1.06B |
| Accounts Payable | $4.30M | $3.02M | $3.38M | $4.97M | $3.40M | $3.48M | $2.35M | $4.03M |
| Deferred Revenue (Current) | $27.22M | $35.07M | $37.59M | $0 | -- | -- | -- | $0 |
| **Total Current Liabilities** | $54.25M | $60.15M | $58.91M | $25.00M | $27.83M | $21.38M | $17.50M | $17.46M |
| Deferred Revenue (Non-Current) | $50K | $1.08M | $8.68M | $0 | -- | -- | -- | -- |
| **Total Non-Current Liabilities** | $17.80M | $19.52M | $27.77M | $19.75M | $20.38M | $20.32M | $20.80M | $21.28M |
| **Total Liabilities** | $72.04M | $79.67M | $86.69M | $44.74M | $48.21M | $41.70M | $38.30M | $38.73M |
| **Total Debt (incl. Leases)** | $20.38M | $20.99M | $21.57M | $22.14M | $22.66M | $22.19M | $22.61M | $23.02M |
| Common Stock | $61K | $61K | $60K | $60K | $60K | $59K | $59K | $59K |
| Retained Earnings | -$419.3M | -$397.7M | -$375.7M | -$351.4M | -$319.4M | -$295.1M | -$261.3M | -$237.8M |
| Accumulated Other Comp. Income | -$6.49M | -$2.31M | $576K | $4.32M | $4.56M | $3.75M | $3.76M | $2.16M |
| **Total Stockholders' Equity** | $911.6M | $928.0M | $941.5M | $956.8M | $976.6M | $990.5M | $1.01B | $1.02B |
| Total Equity | $911.6M | $928.0M | $941.5M | $956.8M | $976.6M | $990.5M | $1.01B | $1.02B |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$113.6M | -$68.99M | -$58.29M | -$63.06M | -$32.67M | -$6.78M |
| Depreciation & Amortization | $2.03M | $2.06M | $1.96M | $841K | $113K | $13K |
| Stock-Based Compensation | $40.22M | $33.02M | $20.00M | $17.20M | $6.91M | $72K |
| Change in Receivables | -- | -- | -- | $0 | $8.00M | -$8.00M |
| Change in Payables | $977K | $1.58M | $277K | -$294K | $2.14M | $14K |
| **Operating Cash Flow** | -$82.23M | -$43.81M | -$50.58M | -$42.92M | -$16.98M | -$4.37M |
| Capital Expenditure | -$1.04M | -$359K | -$1.85M | -$6.45M | -$1.48M | $0 |
| **Free Cash Flow** | -$83.28M | -$44.17M | -$52.42M | -$49.37M | -$18.46M | -$4.37M |
| Purchases of Investments | -$705.2M | -$470.6M | -$317.3M | -$294.4M | -$473.6M | $0 |
| **Investing Cash Flow** | -$301.0M | -$258.0M | -$41.19M | $58.27M | -$341.0M | $0 |
| **Financing Cash Flow** | $4.95M | $713.2M | $59.55M | $500K | $386.5M | $11.52M |
| **Net Change in Cash** | -$378.3M | $411.4M | -$32.22M | $15.84M | $28.59M | $7.16M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$21.57M | -$21.97M | -$24.36M | -$31.95M | -$24.31M | -$33.86M | -$23.51M | -$20.22M |
| Depreciation & Amortization | $458K | $463K | $469K | $468K | $501K | $541K | $519K | $512K |
| Stock-Based Compensation | $8.54M | $9.06M | $9.27M | $9.52M | $9.04M | $10.96M | $10.70M | $6.25M |
| Change in Receivables | -$262K | $34.85M | -$35.00M | -- | $0 | $0 | $0 | -- |
| Change in Payables | $1.28M | -$342K | -$1.61M | $1.67M | -$168K | $1.11M | -$1.64M | $1.56M |
| **Operating Cash Flow** | -$25.18M | $12.48M | -$12.34M | -$28.54M | -$12.86M | -$23.81M | -$17.02M | -$16.73M |
| Capital Expenditure | -$2.0K | -$202K | -$273K | -$106K | -$93K | -$473K | -$371K | -$42K |
| **Free Cash Flow** | -$25.18M | $12.28M | -$12.61M | -$28.65M | -$12.95M | -$24.29M | -$17.39M | -$16.77M |
| Purchases of Investments | -$76.50M | -$144.8M | -$112.8M | -$123.3M | -$118.0M | -$92.69M | -$371.3M | -$24.03M |
| **Investing Cash Flow** | $38.38M | -$38.78M | $8.29M | $29.54M | $8.31M | $1.56M | -$340.4M | $33.93M |
| **Financing Cash Flow** | $852K | $2.24M | $3.54M | $2.94M | $493K | $954K | $554K | $386.6M |
| **Net Change in Cash** | $14.05M | -$24.06M | -$506K | $3.94M | -$4.06M | -$21.30M | -$356.9M | $403.9M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -1576.7% | -933.6% | -902.9% | -779.0% | -905.4% | -- |
| **Net Profit Margin** | -1136.2% | -651.6% | -721.2% | -732.2% | -898.3% | -- |
| Return on Equity (ROE) | -11.9% | -6.7% | -16.9% | -19.7% | -8.9% | -- |
| Return on Assets (ROA) | -11.3% | -6.5% | -15.3% | -17.3% | -8.6% | -41.8% |
| Current Ratio | 39.04x | 59.21x | 26.80x | 20.14x | 29.46x | 5.05x |
| Quick Ratio | 38.67x | 58.72x | 26.40x | 19.81x | 29.30x | 4.97x |
| Debt to Equity | 0.02x | 0.02x | 0.07x | 0.08x | 0.00x | -- |
| **Revenue Growth (YoY)** | -5.6% | +31.0% | -6.1% | +136.8% | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -599.3% | -598.1% | -1143.1% | -1576.7% | -1442.9% | -33002.1% | -1216.6% | -933.6% |
| **Net Profit Margin** | -428.7% | -427.5% | -833.6% | -1136.2% | -1019.0% | -24064.0% | -832.7% | -651.6% |
| Return on Equity (ROE) | -11.0% | -11.1% | -12.2% | -11.9% | -10.4% | -10.7% | -7.7% | -6.7% |
| Return on Assets (ROA) | -10.2% | -10.2% | -11.1% | -11.3% | -9.9% | -10.2% | -7.4% | -6.5% |
| Current Ratio | 17.69x | 16.35x | 17.01x | 39.04x | 35.86x | 47.03x | 58.47x | 59.21x |
| Quick Ratio | 17.44x | 16.14x | 16.83x | 38.67x | 35.54x | 46.59x | 57.94x | 58.72x |
| Debt to Equity | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x |
| **Revenue Growth (YoY)** | -7.1% | -- | -- | -- | +2177.9% | -100.0% | -100.0% | -100.0% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
